Replimune Announces TUDRIQEV Availability in U.S. for Melanoma
Replimune Group Inc. announced that TUDRIQEV is now available in the U.S. for advanced melanoma, supported by the ReplimuneConnect Plus program for eligible patients.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.